Xinwen Chen

This study determines the structure of PEDV S1B bound by neutralizing and non-neutralizing antibodies, revealing how C62 targets a conserved epitope and influences viral entry and neutralization.

This paper introduces GZL626, a novel AR degrader that targets the N-terminal domain and RNF213-UBE2J2 complex, effectively degrading AR and AR-V7 and showing antitumor and antiviral activity.

This study identifies SigH as a key regulator of intrinsic antibiotic resistance in Mycobacterium abscessus through transcriptomic analysis and genetic complementation.

This study evaluates leritrelvir's effectiveness against Mpro variants with resistance mutations, showing it restores dimerization and maintains inhibitory activity better than nirmatrelvir.

This study characterizes the Rc-o319 S-protein's adaptation to R. cornutus ACE2 and identifies structural constraints limiting its ability to bind human ACE2.

This study identifies structural features of affinity-matured R1-32-like antibodies that enable tolerance to SARS-CoV-2 mutations and reveals an ultrapotent antibody with broad variant activity.

This study identifies HGS as a host factor critical for coronavirus infection and discovers RTB as a broad-spectrum antiviral by disrupting HGS-M protein interaction.

This study identifies two ilamycin analogs targeting mycobacterial Clp protease components and discovers mutations conferring resistance to these compounds.

This study shows that disrupting MtrA or MtrB in Mycobacterium abscessus increases antibiotic susceptibility and reduces virulence by affecting cell division and permeability.

This paper discovers a novel quinoline-based PLpro inhibitor, GZNL-2016, that remains effective against drug-resistant SARS-CoV-2 variants like Omicron BA.5 and XBB.1.